521 related articles for article (PubMed ID: 20127709)
21. Rapid up-regulation of c-FLIP expression by BCR signaling through the PI3K/Akt pathway inhibits simultaneously induced Fas-mediated apoptosis in murine B lymphocytes.
Moriyama H; Yonehara S
Immunol Lett; 2007 Mar; 109(1):36-46. PubMed ID: 17275920
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells.
Kim S; Lee TJ; Park JW; Kwon TK
J Cell Biochem; 2008 Nov; 105(4):971-9. PubMed ID: 18767116
[TBL] [Abstract][Full Text] [Related]
24. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
[TBL] [Abstract][Full Text] [Related]
25. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
26. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS
Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254
[TBL] [Abstract][Full Text] [Related]
27. Over-expression of Reticulon 3 (RTN3) enhances TRAIL-mediated apoptosis via up-regulation of death receptor 5 (DR5) and down-regulation of c-FLIP.
Lee JT; Lee TJ; Kim CH; Kim NS; Kwon TK
Cancer Lett; 2009 Jul; 279(2):185-92. PubMed ID: 19250737
[TBL] [Abstract][Full Text] [Related]
28. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.
Siegmund D; Klose S; Zhou D; Baumann B; Röder C; Kalthoff H; Wajant H; Trauzold A
Cell Signal; 2007 Jun; 19(6):1172-84. PubMed ID: 17291719
[TBL] [Abstract][Full Text] [Related]
29. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
30. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
31. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis.
Wang P; Song JH; Song DK; Zhang J; Hao C
Cell Signal; 2006 Sep; 18(9):1528-35. PubMed ID: 16442262
[TBL] [Abstract][Full Text] [Related]
32. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
Shi RX; Ong CN; Shen HM
Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
[TBL] [Abstract][Full Text] [Related]
33. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB.
Ou D; Wang X; Metzger DL; Robbins M; Huang J; Jobin C; Chantler JK; James RF; Pozzilli P; Tingle AJ
Hum Immunol; 2005 Jul; 66(7):799-809. PubMed ID: 16112027
[TBL] [Abstract][Full Text] [Related]
34. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.
Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
Chawla-Sarkar M; Bae SI; Reu FJ; Jacobs BS; Lindner DJ; Borden EC
Cell Death Differ; 2004 Aug; 11(8):915-23. PubMed ID: 15118763
[TBL] [Abstract][Full Text] [Related]
36. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.
MacFarlane M; Harper N; Snowden RT; Dyer MJ; Barnett GA; Pringle JH; Cohen GM
Oncogene; 2002 Oct; 21(44):6809-18. PubMed ID: 12360407
[TBL] [Abstract][Full Text] [Related]
38. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K
Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868
[TBL] [Abstract][Full Text] [Related]
39. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
40. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
Ozören N; El-Deiry WS
Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]